Oncotelic Therapeutics, Inc.
https://www.oncotelic.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Oncotelic Therapeutics, Inc.
HealthCap’s Steen On Growing Successful Precision Medicine Businesses
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.
$55m For Akebia As Otsuka Confirms Vadadustat Exit
Japanese firm extricates itself from international deals for oral anemia drug, leaving Akebia potentially needing to find a new partner to progress development and commercialization.
Keeping Track: US FDA Okays Alnylam’s siRNA Amvuttra, Alopecia Claim For Lilly’s Olumiant; Sierra Submits Momelotinib
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey
Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Mateon Therapeutics, Inc.
- OXiGENE, Inc.
- PointR Data, Inc.